Ятрогенний остеопороз. Частина ІІІ

Автор(и)

  • N. V. Grygorieva ДУ «Інститут геронтології імені Д. Ф. Чеботарьова НАМН України», Київ, Україна

DOI:

https://doi.org/10.37987/1997-9894.2018.9(225-6).200368

Ключові слова:

ятрогенний остеопороз, гормональні контрацептиви, агоністи / антагоністи гонадотропін-рилізинг гормону, інгібітори ароматази, глюкокортикоїди, профілактика, лікування

Анотація

У третій (заключній) частині даного огляду представлений аналіз сучасних літературних даних щодо впливу гормональних контрацептивів на темпи формування й втрати кісткової тканини у жінок різного віку. Продемонстровано вплив агоністів / антагоністів гонадотропін-рилізинг гормону, інгібіторів ароматази, які використовують у комплексному лікуванні онкологічної патології жінок і чоловіків, на показники кісткової тканини, темпи її ремоделювання й ризик остеопоротичних переломів. Представлені загальні підходи до ведення пацієнтів з ятрогенним остеопорозом, а також проаналізовані сучасні стратегії профілактики та лікування глюкокортикоїд-індукованого остеопорозу і остеопорозу, пов’язаного із застосуванням інгібіторів ароматази та агоністів / антагоністів гонадотропін-рилізинг гормону.

Біографія автора

N. V. Grygorieva, ДУ «Інститут геронтології імені Д. Ф. Чеботарьова НАМН України», Київ

Н. В. Григор’єва

Посилання

The Impact of Contraceptive Counseling in Primary Care on Contraceptive Use //

J. K. Lee, S. M. Parisi, A. Y. Akers [et al.] // J. Gen. Intern. Med. – 2011. – No. 26

(7). – P. 731–736.

Wiegratz I. Hormonal Contraception – What Kind, When, and for Whom? /

I. Wiegratz, C. J. Thaler // Dtsch. Arztebl. Int. – 2011. – No. 108 (28–29). –

P. 495–506.

Григорьева Н. В. Гормональная контрацепция и костная ткань / Н. В. Григорьева //

Боль. Суставы. Позвоночник. – 2013. – № 1 (9). – С. 39–57.

Bone mineral density in adolescent females using depot medroxyprogesterone

acetate / E. Lara-Torre, C. P. Edwards, S. Perlman, S. P. Hertweck // J. Pediatr.

Adolesc. Gynecol. – 2004. – No. 17. – Р. 17–21.

Oral contraceptive use by teenage women does not affect peak bone mass: a

longitudinal study / T. Lloyd, D. S. Taylor, H. M. Lin [et al.] // Fertil. Steril. – 2000. –

No. 74. – Р. 734–738.

Bone biochemical markers in adolescent girls using either depot

medroxyprogesterone acetate or an oral contraceptive / E. Rome, J. Ziegler,

M. Secic [et al.] // J. Pediatr. Adolesc. Gynecol. – 2004. – No. 17. – Р. 373–377.

Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density

in a cohort of adolescent girls / B. A. Cromer, M. Stager, A. Bonny [et al.] // J.

Adolesc. Health. – 2004. – No. 35. – Р. 434–441.

Effect of two kinds of different combined oral contraceptives use on bone mineral

density in adolescent women / L. Gai, Y. Jia, M. Zhang [et al.] // Contraception. –

– No. 86(4). – P. 332–336.

One-year adolescent bone mineral density and bone formation marker

changes through the use or lack of use of combined hormonal contraceptives /

A. D. C. B. Rizzo, T. B. L. Goldberg, T. P. Biason [et al.] // J. Pediatr (Rio J.). – 2018.

– P. S0021–7557(18)30069-X.

Ziglar S. The effect of hormonal oral contraception on acquisition of peak bone

mineral density of adolescents and young women / S. Ziglar, T. S. Hunter // J.

Pharm. Pract. – 2012. – No. 25(3). – P. 331–340.

The effect of past use of oral contraceptive on bone mineral density, bone

biochemical markers and muscle strength in healthy pre- and postmenopausal

women / F. Allali, L. El Mansouri, F. Z. Abourazzak [et al.] // BMC Womens Health.

– 2009. – No. 9. – Р. 31–34.

Bedford J. L. The relationship between 24-hr urinary cortisol and bone in healthy

young women / J. L. Bedford, S. I. Barr // Int. J. Behav. Med. – 2010. – No. 17 (3).

– Р. 207–215.

Oral Contraceptive Use and Bone Density Change in Adolescent and Young

Adult Women: A Prospective Study of Age, Hormone Dose, and Discontinuation /

D. Scholes, R. A. Hubbard, L. E. Ichikawa [et al.] // J. Clin. Endocrinol. Metab. –

– No. 96 (9). – P. 1380–1387.

A three-year longitudinal evaluation of the forearm bone density of users of

etonogestrel- and levonorgestrel-releasing contraceptive implants / C. MonteiroDantas, X. Espejo-Arce, J. F. Lui-Fil [et al.] // Reprod Health. – 2007. – No. 4. –

P. 11–16.

Bone Mineral Density in Adolescent Females Using Injectable or Oral

Contraceptives: A 24 Month Prospective Study / B. A. Cromer, A. E. Bonny,

M. Stager [et al.] // Fertil. Steril. – 2008. – No. 90 (6). – P. 2060–2067.

Pasco J.A. Oral contraceptives and bone mineral density: a population-based study /

J. A. Pasco, M. A. Kotowicz, M. J. Henry [et al.] // Am. J. Obstet. Gynecol. –

– No. 182. – Р. 265–269.

Oral contraceptives and bone mineral density in white and black women in

CARDIA / K. L. Cobb, J. L. Kelsey, S. Sidney [et al.] // Osteoporos. Int. – 2002. –

No. 13. – Р. 893–900.

Oral contraceptive use and bone mineral density in premenopausal women: crosssectional, population-based data from the Canadian Multicentre Osteoporosis

Study / J. C. Prior, S. A. Kirkland, L Joseph [et al.] // CMAJ. – 2001. – 165. –

Р. 1023–1029.

Steroid hormone contraception and bone mineral density: a cross-sectional study

in an international population / D. B. Petitti, G. Piaggio, S. Mehta [et al.] // Obstet.

Gynecol. – 2000. – No. 95. – Р. 736–744.

Status of bone mineral density after the long-standing application of contraception

Depo-Provera / S. Zeman, P. Havlík, J. Zemanová, D. Němec // Ceska Gynekol. –

– No. 78 (1). – P. 116–124.

Modesto W. Prevalence of Low Bone Mass and Osteoporosis in Long-Term Users of

the Injectable Contraceptive Depot Medroxyprogesterone Acetate / W. Modesto,

M.V. Bahamondes, L. Bahamondes // J. Womens Health (Larchmt). – 2015. –

No. 24 (8). – P. 636–640.

Effects of a low-dose and ultra-low-dose combined oral contraceptive use on

bone turnover and bone mineral density in young fertile women: a prospective

controlled randomized study / C. Nappi, A. Di Spiezio Sardo, G. Acunzo [et al.] //

Contraception. – 2003. – No. 67. – Р. 355–359.

Effects of an oral contraceptive containing drospirenone on bone turnover and

bone mineral density / C. Nappi, A. Di Spiezio Sardo, E. Greco [et al.] // Obstet.

Gynecol. – 2005. – No. 105. – Р. 53–60.

A 3 year double-blind randomized controlled study on the influence of 2 oral

contraceptives containing either 20 µg or 30 µg ethinylestradiol in combination with

levonorgestrel on bone mineral density / J. Endrikat, E. Mih, B. Dusterberg [et al.] //

Contraception. – 2004. – No. 69. – Р. 179–187.

Longitudinal evaluation of perimenopausal bone loss: effects of a low-dose

oral contraceptive preparation on bone mineral density and metabolism / M.

Gambacciani, M. Ciaponi, B. Cappagli [et al.] // Osteoporos. Int. – 2000. –

No. 11. – Р. 544–548.

Bone mineral density in young, hypothalamic oligoamenorrheic women treated with

oral contraceptives / C. Castelo-Branco, J. J. Vicente, F. Pons [et al.] // J. Reprod.

Med. – 2001. – No. 46. –Р. 875–879.

Effects of oral contraceptives on body composition and physical performance

in female athletes / A. Rickenlund, K. Carlstrom, B. Ekblom [et al.] // J. Clin.

Endocrinol. Metab. – 2004. – No. 89. – Р. 4364–4370.

Effects of a triphasic combination oral contraceptive containing norgestimate/

ethinyl estradiol on biochemical markers of bone metabolism in young women with

osteopenia secondary to hypothalamic amenorrhea / S. K. Grinspoon, A. J. Friedman,

K. K. Miller [et al.] // J. Clin. Endocrinol. Metab. – 2003. – No. 88. – Р. 3651–3656.

Oestrogen replacement improves bone mineral density in oligo-amenorrhoeic

athletes: a randomised clinical trial / K. E. Ackerman, V. Singhal, C. Baskaran

[et al.] // Br. J. Sports Med. – 2018. – P. bjsports-2018-099723.

Treatments to Prevent Bone Loss in Functional Hypothalamic Amenorrhea: A

Systematic Review and Meta-Analysis / O. Altayar, A. Al Nofal, B. G. Carranza

Leon [et al.] // J. Endo. – 2017. – No. 1 (5). – P. 500–511.

The effect of estrogen-progestin treatment on bone mineral density in anorexia

nervosa / N. H. Golden, L. Lanzkowsky, J. Schebendach [et al.] // J. Pediatr.

Adolesc. Gynecol. – 2002. – No. 15. – Р. 135–143.

Vestergaard P. Oral contraceptive use and risk of fractures / P. Vestergaard,

L. Rejnmark, L. Mosekilde // Contraception. – 2006. – No. 73 (6). – Р. 571–576.

Vestergaard P. Fracture risk in very young women using combined oral

contraceptives / P. Vestergaard, L. Rejnmark, L. Mosekilde // Contraception. –

– No. 78 (5). – P. 358–364.

Oral contraceptive use and fracture risk around the menopausal transition /

D. Scholes, A. Z. LaCroix, R. A. Hubbard [et al.] // Menopause. – 2016. – No. 23

(2). – P. 166–174.

Oral contraceptive use and fracture risk-a retrospective study of 12,970 women in

the UK / S. Dombrowski, L. Jacob, P. Hadji, K. Kostev // Osteoporos. Int. – 2017. –

No. 28 (8). – P. 2349–2355.

Steroidal contraceptives: effect on bone fractures in women / L. M. Lopez, D. A. Grimes, K. F. Schulz [et al.] // Cochrane Database Syst. Rev. – 2014. – No.

(6). – P. CD006033.

WHO Statement on Hormonal Contraception and Bone Health,

http://www.who.int/reproductivehealth/publications/family_planning/

hc_bone_health/en/index.html, 2005.

Cancer Treatment–Induced Bone Loss in Women With Breast Cancer and Men With

Prostate Cancer / P. Taxel, E. Aircloth, S. Idrees, C. Van Poznak // J. Endocr. Soc. –

– No. 2 (7). – P. 574–588. DOI: 10.1210/js.2018-00052.

Bone loss following hypogonadism in men with prostate cancer treated with GnRH

analogs / D. Mittan, S. Lee, E. Miller [et al.] // J. Clin. Endocrinol. Metab. – 2002. –

No. 87. – Р. 3656–3661.

Bone loss after initiation of androgen deprivation therapy in patients with prostate

cancer / S. L. Greenspan, P. Coates, S. M. Sereika [et al.] // J. Clin. Endocrinol.

Metab. – 2005. – No. 90. – Р. 6410–6417.

Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone

agonists / S. A. Stoch, R. A. Parker, L. Chen [et al.] // J. Clin. Endocrinol. Metab. –

– No. 86. – Р. 2787–2790.

The prevention of fragility fractures in patients with non-metastatic prostate cancer:

a position statement by the international osteoporosis foundation / L. Cianferotti,

F. Bertoldo, M. Carini [et al.] // Oncotarget. – 2017. – No. 8 (43). – Р. 75646–75663.

Prevalence of osteoporosis in prostate cancer survivors: a meta-analysis /

A. C. Lassemillante, S. A. Doi, J. D. Hooper [et al.] // Endocrine. – 2014. – No. 45

(3). – Р. 370–381.

Cancer treatmentinduced bone loss in breast and prostate cancer / F. Saad,

J. D. Adachi, J. P. Brown [et al.] // J. Clin. Oncol. – 2008. – No. 26 (33). –

Р. 5465–5476.

Hip fractures in men with prostate cancer treated with orchiectomy / P. W. Dickman,

J. Adolfsson, K. Astrom, G. Steineck // J. Urol. – 2004. – No. 172. – Р. 2208–2212.

Risk of fracture after androgen deprivation for prostate cancer / V. B. Shahinian,

Y. F. Kuo, J. L. Freeman, J. S. Goodwin // N. Engl. J. Med. – 2005. – No. 352. –

Р. 154–164.

Risk of fracture in men with prostate cancer on androgen deprivation therapy:

a population-based cohort study in New Zealand / A. Wang, Z. Obertov´a,

C. Brown [et al.] // BMC Cancer. – 2015. – No. 15(1). – Р. 837.

Fracture after androgen deprivation therapy among men with a high baseline risk of

skeletal complications / Y. H. Shao, D. F. Moore, W. Shih [et al.] // BJU Int. – 2013.

– No. 111 (5). – Р. 745–752.

Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two

Extension Studies / E. Surrey, H. S. Taylor, L. Giudice [et al.] // Obstet. Gynecol. –

– No. 132 (1). – Р. 147-160.

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after

completion of 5 years’ adjuvant treatment for breast cancer / A. Howell, J. Cuzick,

M. Baum [et al.] // Lancet. – 2005. – No. 365. – Р. 60–62.

Improved overall survival in postmenopausal women with early breast cancer

after anastrozole initiated after treatment with tamoxifen compared with continued

tamoxifen: the ARNO 95 Study / M. Kaufmann, W. Jonat, J. Hilfrich [et al.] // J. Clin.

Oncol. – 2007. – No. 25. – Р. 2664–2670.

Switching to anastrozole versus continued tamoxifen treatment of early breast

cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial /

F. Boccardo, A. Rubagotti, M. Puntoni [et al.] // J. Clin. Oncol. – 2005. –

No. 23. – Р. 5138–5147.

Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen

treatment (Intergroup Exemestane Study): a randomised controlled trial /

R. C. Coombes, L. S. Kilburn, C. F. Snowdon [et al.]; Intergroup Exemestane Study //

Lancet. – 2007. – No. 369. – Р. 559–570.

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy

in receptor-positive breast cancer: updated findings from NCIC CTG MA. 17 /

P. E. Goss, J. N. Ingle, S. Martino [et al.] // J. Natl. Cancer Inst. – 2005. – No. 97. –

Р. 1262–1271.

Five years of letrozole compared with tamoxifen as initial adjuvant therapy for

postmenopausal women with endocrine-responsive early breast cancer: update

of study BIG 1-98 / A. S. Coates, A. Keshaviah, B. Thurlimann [et al.] // J. Clin.

Oncol. – 2007. – No. 25. – Р. 486–492.

Switching of postmenopausal women with endocrine-responsive early breast cancer

to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial

and ARNO 95 trial / R. Jakesz, W. Jonat, M. Gnant [et al.]; ABCSG and the

GABG // Lancet. – 2005. – No. 366. – Р. 455–462.

Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results

of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230) / R.

Eastell, R.A. Hannon, J. Cuzick [et al.]; ATAC Trialists’ group // J. Bone Miner. Res. –

– No. 21. – Р. 1215–1223.

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and

fracture incidence in postmenopausal women with early breast cancer participating

in the Intergroup Exemestane Study (IES): a randomized controlled study /

R. E. Coleman, L. M. Banks, S. I. Girgis [et al.]; Intergroup Exemestane Study

group // Lancet Oncology. – 2007. – No. 8. – Р. 119–127.

Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion

study to NCIC CTG MA.17 / E. A. Perez, R. G. Josse, K. I. Pritchard [et al.] // J. Clin.

Oncol. – 2006. – No. 24. – Р. 3629–3635.

The effect of tamoxifen or exemestane on bone mineral density during the first 2 years

of adjuvant treatment of postmenopausal women with early breast cancer / S. Jones,

C. Stokoe, M. Sborov [et al.] // Clin. Breast Cancer. – 2008. – No. 8. – Р. 527–532.

Changes in bone turnover and in bone mass in women with breast cancer switched

from tamoxifen to exemestane / S. Gonnelli, A. Cadirni, C. Caffarelli [et al.] //

Bone. – 2007. – No. 40. – Р. 205–210.

Effects of third generation aromatase inhibitors on bone health and other safety

parameters: results of an open, randomised, multi-centre study of letrozole,

exemestane and anastrozole in healthy postmenopausal women /

E. V. McCloskey, R. A. Hannon, G. Lakner [et al.] // Eur. J. Cancer. – 2007. –

No. 43. – Р. 2523–2531.

A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone

metabolism in postmenopausal women with estrogen receptor-positive breast

cancer / F. M. McCaig, L. Renshaw, L. Williams [et al.] // Breast Cancer Res. Treat.

– 2010. – No. 119. – Р. 643–651.

Panday K. Medication-induced osteoporosis: screening and treatment strategies /

K. Panday, A. Gona, M. B. Humphrey // Ther. Adv. Musculoskelet. Dis. – 2014. –

No. 6 (5). – Р. 185–202.

American College of Rheumatology Guideline for the Prevention and

Treatment of Glucocorticoid-Induced Osteoporosis / L. Buckley, G. Guyatt,

H. A. Fink [et al.] // Arthritis Rheumatol. – 2017. – No. 69 (8). – Р. 1521–1537.

update of recommendations on the prevention and treatment of glucocorticoidinduced osteoporosis / K. Briot, B. Cortet, C. Roux [et al.]; Bone Section of the French

Society for Rheumatology (SFR) and Osteoporosis Research and Information Group

(GRIO) // Joint Bone Spine. – 2014. – No. 81 (6). –P. 493–501.

Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis /

R. M. Pereira, J. F. Carvalho, A. P. Paula [et al.]; Committee for Osteoporosis

and Bone Metabolic Disorders of the Brazilian Society of Rheumatology,

Brazilian Medical Association; Brazilian Association of Physical Medicine and

Rehabilitation // Rev. Bras. Reumatol. – 2012. – No. 52 (4). –P. 580–593.

Guide for the prevention and treatment of glucocorticoid-induced osteoporosis

of the Spanish Society of Internal Medicine / M. Sosa Henríquez, M. Díaz Curiel,

A. Díez Pérez [et al.]; Sociedad Española de Medicina Interna // Rev. Clin. Esp. –

– No. 208(1). – P. 33–45.

Arora E. Impact of antiepileptic drugs on bone health: Need for monitoring,

treatment, and prevention strategies / E. Arora, H. Singh, Y. Kumar Gupta //

J. Family Med. Prim. Care. – 2016. – No. 5 (2). – P. 248–253.

Григорьева Н. В. Ятрогенный остеопороз. Часть І. / Н. В. Григорьева //

Ліки України. – 2018. – № 5–6. – С. 30–37.

Osteoporosis in men: an Endocrine Society clinical practice guideline / N. B. Watts,

R. A. Adler, J. P. Bilezikian [et al.]; Endocrine Society // J. Clin. Endocrinol. Metab. –

– No. 97 (6). – P. 1802–1822.

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate

cancer / M. R. Smith, F. J. McGovern, A. L. Zietman [et al.] // N. Engl. J. Med. –

– No. 345. – Р. 948–955.

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving

androgen deprivation therapy for nonmetastatic prostate cancer / M. R. Smith,

J. Eastham, D. M. Gleason [et al.] // J. Urol. – 2003. – No. 169. – Р. 2008–2012.

A randomized, placebo-controlled trial of zoledronic acid in patients with hormonerefractory metastatic prostate carcinoma / F. Saad, D. M. Gleason, R. Murray [et

al.] // J. Natl. Cancer Inst. – 2002. – No. 94. – Р. 1458–1468.

Effect of once-weekly oral alendronate on bone loss in men receiving androgen

deprivation therapy for prostate cancer: a randomized trial / S. L. Greenspan,

J. B. Nelson, D. L. Trump, N. M. Resnick // Ann. Intern. Med. – 2007. – No. 146. –

Р. 416–424.

Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone

loss in men with prostate cancer: a randomized controlled trial / M. R. Smith,

M. A. Fallon, H. Lee, J. S. Finkelstein // J. Clin. Endocrinol. Metab. – 2004. –

No. 89. – Р. 3841–3846.

Positive fracture reduction trial of toremifene 80 mg in men on ADT demonstrates

significant fracture risk in untreated placebo group / D. W. Lin, L. S. Marks,

R. A. Morton, D. Rodriguez // J. Urol. – 2009. – No. 181. – Р. 229.

Denosumab in men receiving androgen-deprivation therapy for prostate cancer /

M. R. Smith, B. Egerdie, N. Herna´ndez Toriz [et al.] // N. Engl. J. Med. – 2009. –

No. 361. – Р. 745–755.

Denosumab and bone-metastasis-free survival in men with castration-resistant

prostate cancer: results of a phase 3, randomised, placebo-controlled trial /

M. R. Smith, F. Saad, R. Coleman [et al.] // Lancet. – 2012. – No. 379. – Р. 39–46.

Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE

trial / C. Van Poznak, R. A. Hannon, J. R. Mackey [et al.] // J. Clin. Oncol. – 2010. –

No. 28. – Р. 967–975.

Prevention of anastrozole-induced bone loss with monthly oral ibandronate during

adjuvant aromatase inhibitor therapy for breast cancer / J. E. Lester, D. Dodwell,

O. P. Purohit [et al.] // Clin. Cancer Res. – 2008. – No. 14. – Р. 6336–6342.

Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in

postmenopausal women with early breast cancer receiving adjuvant letrozole:

Z-FAST study 36-month follow-up results / A. M. Brufsky, L. D. Bosserman,

R. R. Caradonna [et al.] // Clin. Breast Cancer. – 2009. – No. 9. – Р. 77–85.

Integrated analysis of zoledronic acid for prevention of aromatase inhibitorassociated bone loss in postmenopausal women with early breast cancer receiving

adjuvant letrozole / A. Brufsky, N. Bundred, R. Coleman [et al.]; Z-FAST and ZOFAST Study Groups // Oncologist. – 2008. – No. 13. – Р. 503–514.

Santen R. J. Clinical review: Effect of endocrine therapies on bone in breast cancer

patients / R. J. Santen // J. Clin. Endocrinol. Metab. – 2011. – No. 96 (2). –

Р. 308–319.

The effect of zoledronic acid on aromatase inhibitor-associated bone loss in

premenopausal women with early breast cancer receiving adjuvant letrozole: the

Z-FAST study 5 year final follow up / A. Brufsky, G. Harker, J. T. Beck [et al.] // San

Antonio Breast Cancer Symposium, San Antonio, TX, 2009 (Abstract 4083).

Lack of evidence for fracture prevention in early breast cancer bisphosphonate

trials: a meta-analysis / A. Valachis, N. P. Polyzos, V. Georgoulias [et al.] //

Gynecol. Oncol. – 2010. – No. 117. – Р. 139–145.

Effect of denosumab on bone mineral density in women receiving adjuvant

aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a

phase 3 study / G. K. Ellis, H. G. Bone, R. Chlebowski [et al.] // Breast Cancer Res.

Treat. – 2009. – No. 118. – Р. 81–87.

Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors

for nonmetastatic breast cancer / G. K. Ellis, H. G. Bone, R. Chlebowski [et al.] // J.

Clin. Oncol. – 2008. – No. 26. – Р. 4875–4882.

Gnant M. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre,

randomised, double-blind, placebo-controlled trial / M. Gnant, G. Pfeiler,

P. C. Dubsky [et al.]; Austrian Breast and Colorectal Cancer Study Group // Lancet.

– 2015. – No. 386 (9992). – Р. 433–443.

Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in

postmenopausal women with hormone sensitive breast cancer: Joint position

statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG / P. Hadji,

M. S. Aapro [et al.] // J. Bone Oncol. – 2017. – No. 7. – Р. 1–12.

Practical guidance for the management of aromatase inhibitor-associated bone

loss / P. Hadji, J. J. Body, M. S. Aapro [et al.] // Ann. Oncol. – 2008. – No. 19 (8). –

P. 1407–1416.

##submission.downloads##

Опубліковано

2018-12-07

Як цитувати

Grygorieva, N. V. (2018). Ятрогенний остеопороз. Частина ІІІ. Ліки України, (9(225-6), 27–40. https://doi.org/10.37987/1997-9894.2018.9(225-6).200368

Номер

Розділ

ЛЕКЦІЇ, ОГЛЯДИ